StockWatch: Patient Death, Rival’s Patent Challenge Sink Erasca Shares

A 66-year-old male patient died after his grade 3 treatment-related adverse event (TRAE) of pneumonitis progressed to grade 5 after supportive care was withdrawn at the patient’s direction. The patient, who had “heavily pretreated” metastatic pancreatic cancer, received 24 mg of ERAS-0015, Erasca said. The post StockWatch: Patient Death, Rival’s Patent Challenge Sink Erasca Shares appeared first on GEN - Genetic Engineering and Biotechnology News.